The financing will enable the company to advance its lead candidate to the clinic and to build a pipeline of next-generation antibody-drug conjugates (ADCs) Its proprietary ADC technology opens the …
Mablink Bioscience appoints Dr. Lenka Kyrych Sadilkova as its Head of Preclinical Research and Development to support the development of its pipeline of ADC candidates using its proprietary PSARlink™ linker …
Mablink Bioscience appoints its Chief Development Officer to support the regulatory development of its lead candidate MBK-103, an ADC using its proprietary PSARlink™ linker Lyon, France, March 1, 2022 Mablink …
Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s proprietary PSARlink™ drug-linker technology Lyon, France & Duisburg, Germany, October 21, 2021 Mablink Bioscience S.A.S. a …
Mablink Bioscience to move forward its ADC pipeline targeted at cancers with high unmet medical needs Lyon, France, April 27, 2021 Mablink Bioscience, a company developing the next generation of …
Le quotidien “Le Figaro” s’est fait l’écho de l’engouement de l’industrie pharmaceutique pour l’approche ADC (anticorps conjugués) dans un article publié le 3 mars : lien vers l’article. Mablink est …
We are pleased to announce a strategic addition to Mablink’s team with the arrival of Edouard Leroy as our Chief Business Development Officer.
Mablink is adopting Agatha’s solution, a global leader in quality and content management solutions for life sciences.
